Background-Introduction of a universal varicella vaccine program for U.S. children in 1996 sparked concern that less-frequent exposure to varicella would decrease external boosting of immunity to varicella zoster virus and thereby increase incidence of herpes zoster (HZ).
Although HZ can lead to serious ocular and neurologic complications (4), the most common complication is postherpetic neuralgia. Approximately 12% to 24% of older adults with HZ have persistent pain 90 days or more after onset of rash. This chronic pain can lead to substantial distress and functional limitations, with detrimental effects on quality of life (5) .
In 1996, the U.S. Advisory Committee on Immunization Practices first recommended routine varicella vaccination for children aged 12 to 18 months (6) . Vaccination of healthy children is routinely recommended in several countries, including Canada, Australia, Germany, and South Korea; however, some European countries reserve vaccination for susceptible adolescents or adults in whom risk for severe disease is higher or have no routine recommendation because of doubts about the importance of the disease burden and about the cost-effectiveness of the vaccine (7).
Hope-Simpson (8) hypothesized that exposure to varicella would decrease risk for HZ through boosting VZV-specific immunity. Subsequent studies (9) (10) (11) have shown decreased risk for HZ in adults who live with children or have known varicella contacts; other studies (12, 13) have not shown this effect. Mathematical models that incorporate external boosting have predicted that introduction of a universal varicella vaccine program for children would lead to adults being exposed to children with varicella less frequently and increase HZ incidence in adults (9, 14) . The U.K. Health Protection Agency has raised concerns that adding the varicella vaccine to their childhood immunization program would lead to an increase in HZ in adults (15) .
In the United States, several studies spanning 1945 to 2006 have reported increased HZ incidence (3, (16) (17) (18) (19) . Temporal increases in HZ incidence have also been reported in countries without a varicella vaccination program (20) . However, no studies have shown an increase in HZ incidence after varicella vaccination compared with an adequate baseline before introduction of the vaccine. In 2006, the U.S. Advisory Committee on Immunization Practices recommended HZ vaccination for adults aged 60 years or older to prevent HZ and its sequelae (21) . However, as of 2010, only 14.4% of adults aged 60 years or older have received the vaccine (22) .
We used Medicare claims data from 1992 through 2010 to evaluate trends in HZ incidence in the U.S. population older than 65 years and determine any influence of the varicella vaccination program on these trends. We also examined the influence of age, sex, and race or ethnicity on HZ incidence.
Methods

Study Population
We obtained health care claims data on a 5% random sample of Medicare beneficiaries maintained in the Centers for Medicare & Medicaid Services Chronic Conditions Data Warehouse (23) . The study population comprised U.S. residents in the 5% random sample who were older than 65 years and had more than 1 calendar year of continuous enrollment in Medicare fee-for-service Parts A and B between 1991 and 2010. The data included claims generated in outpatient, inpatient, skilled nursing facility, and home health settings. Selfreported race and ethnicity data come from U.S. Social Security Administration records. Mutually exclusive categories included white (non-Hispanic); black (non-Hispanic); Hispanic; Asian, Asian American, or Pacific Islander; American Indian or Alaska Native; or other (24).
Definition and Calculation of HZ Incidence
We defined incident HZ in a given year as the first occurrence of an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), code (any position) for HZ (053.xx) in any health care setting with no HZ code during the previous calendar year. Claims with a code for postherpetic neuralgia (053.12 or 053.13) were excluded. We calculated incidence as the number of incident cases of HZ divided by the total person-years. Because we required 1 calendar year of enrollment without HZ before defining an incident case, the calculation of HZ incidence included beneficiaries beginning at age 66 years. We standardized HZ incidence by age and sex using the 2000 U.S. standard population (25, 26) .
Analysis of HZ Incidence in an Immunocompetent Subgroup
Herpes zoster is more common in immunocompromised persons (21, 27) . To exclude the possibility that changes in HZ incidence were due to changes in the prevalence of immunosuppression, we performed a separate analysis restricted to a selected cohort of beneficiaries who were least likely to be immunocompromised. This analysis excluded beneficiaries with an ICD-9-CM code indicating any potentially immunocompromising condition or any condition that could potentially be managed with immunosuppressive treatments or corticosteroids (Appendix Table, available at www.annals.org) (19) . Our definition was artificial but ensured that beneficiaries remaining in this analysis were not immunocompromised. We standardized HZ incidence in this population by age and sex using the 2000 U.S. standard population (25, 26) .
Assessing the Effect of Health-Seeking Behavior or Medicare on Temporal Increases in HZ Incidence
Because cases of HZ identified through administrative data are medically attended, changes in HZ incidence can be due to changes relating to the Medicare program or to health-seeking behavior. To control for such changes, we compared trends in incidence of HZ with those of 10 preselected conditions, which, like HZ, are common and acute and typically managed in outpatient settings (19) . We identified first instances of HZ and the selected conditions as the first occurrence of the corresponding ICD-9-CM codes in outpatient settings in the primary or secondary positions, with no code for the condition in the previous 4 calendar years. We derived annual incidence standardized by age and sex from the 2000 U.S. standard population and calculated ratios of HZ incidence to the incidence of each selected condition.
Analysis of HZ Incidence Trends
We used Poisson regression analysis to compare HZ trends during 3 periods of varicella vaccination program implementation: preimplementation (1992 to 1995), early implementation (1996 to 1999), and full implementation (2000 to 2010). The model included age group, sex, calendar year, indicator variables for implementation period, and interactions between calendar year and the indicator variables. We used generalized estimating equations (GEEs) to account for correlated data within states. The parameter estimates for the interaction terms allow us to compare the annual rate of increase in HZ incidence during early and full implementation periods with the rate of increase during the preimplementation period (28), adjusting for age and sex.
Assessing Potential Risk Factors for HZ and Influence of State-Level Varicella Vaccination Coverage on HZ Incidence
To evaluate risk factors for HZ, we calculated adjusted RRs for age, sex, and race or ethnicity using Poisson regression analysis with GEEs to account for correlated data within states. We limited this analysis to the period before introduction of the universal varicella vaccination program (1992 to 1996) to exclude any possibility of bias due to implementation of the program.
We examined the effect of state varicella vaccination coverage on HZ incidence during the period after implementation of the varicella vaccination program (1997 to 2010). We obtained rates of annual 1-dose varicella vaccination coverage for children aged 19 to 35 months for each of the 50 states and the District of Columbia from the National Immunization Survey (19, 29) . We calculated the RR of state vaccine coverage (expressed as a percentage) for HZ incidence, adjusted for age, sex, and calendar year by using Poisson regression with GEEs to account for statistical dependence of measurements within states. To evaluate whether increasing varicella vaccination coverage had a delayed effect on HZ incidence, which previous models (9) suggested, we replaced concurrent vaccination coverage with coverage lagged by 10 years and ran the same model.
The Centers for Disease Control and Prevention Human Subjects Coordinator determined that this study did not require review for human subjects protections because the data did not contain personal identifiers and were not originally collected specifically for this study. We used SAS, version 9.3 (SAS Institute, Cary, North Carolina), for all data management and statistical analyses. Poisson regression analyses with GEEs were performed using PROC GENMOD in SAS software.
Role of the Funding Source
No external funding was obtained for this study.
Results
The study included 2 845 353 Medicare beneficiaries from 1992 through 2010, contributing a total of 22 508 343 person-years with a median of 7 years per beneficiary (Table 1) . Age and sex distributions were similar to the entire Medicare population but with fewer beneficiaries in western states and fewer Hispanic and Asian beneficiaries (data not shown). The mean age was 76.1 years in 1992 and 77.1 years in 2010.
A total of 281 317 incident cases of HZ occurred. Crude HZ incidence increased 40% from 10.2 per 1000 person-years in 1992 to 14.3 per 1000 persons in 2010; age-and sexstandardized HZ incidence increased 39% from 10.0 per 1000 person-years in 1992 to 13.9 per 1000 person-years in 2010 ( Figure) . Mean age at the time of HZ diagnosis remained stable at 76.9 years in 1992 and 77.9 years in 2010. The exponentiated parameter estimate for the interaction between calendar year and the indicator variable for the early varicella vaccine implementation period was 1.002 (95% CI, 0.984 to 1.020), indicating that the annual rate of increase in HZ incidence during this period (1996 to 1999) was 0.2% higher than that during the preimplementation period (1992 to 1995) but was not statistically significant. Similarly, the exponentiated parameter estimate for the interaction between calendar year and the indicator variable for full implementation period (2000 to 2010) was 1.008 (CI, 0.994 to 1.023).
Increases occurred among all age groups ( Figure) , racial or ethnic groups, and census divisions (data not shown) and both sexes; they remained apparent even in the selected 30% of beneficiaries without a potentially immunocompromising condition (Appendix Figure 1 , available at www.annals.org). In addition, increases in HZ incidence were greater than those seen in 9 out of 10 analogous conditions that we investigated (Appendix Figure 2 , available at www.annals.org). Table 2 shows data on the incidence of HZ among Medicare beneficiaries in 2010 to highlight the incidence of HZ in key subgroups.
We evaluated HZ incidence by sex, age group, and race or ethnicity (Table 3) 
Discussion
Varicella exposure has been postulated to boost VZV-specific immunity and reduce the risk for VZV reactivation. Concern has been expressed that routine childhood varicella vaccination, introduced in the United States in 1996, could thereby lead to an increase in HZ incidence by reducing opportunities for exposure to varicella. Our findings suggest that, although HZ incidence has increased in elderly persons, routine varicella vaccination has not influenced this increase.
First, the rise in HZ incidence clearly predates 1996 and HZ incidence did not accelerate after implementation of the varicella vaccination program, when varicella vaccination coverage reached 90% and varicella incidence decreased by 90% (30, 31) . Second, state varicella vaccination coverage had no effect on HZ incidence concurrently or 10 years later. Finally, the mean age at the time of HZ diagnosis did not decrease during the study, which might occur if external boosting helped to maintain protection. Thus, although HZ incidence has increased in the elderly population, we did not find evidence to suggest that this increase has been influenced by the varicella vaccination program in the United States. This finding confirms the results of other studies before and after introduction of the varicella vaccine (19, (32) (33) (34) .
The lack of evidence for an effect of the varicella vaccination program on HZ incidence might be explained in several ways. First, although some studies suggest that exposure to varicella protects against HZ (9-11), other findings contradict this (12, 13) . Because latent VZV can reactivate subclinically and boost immunity (35) (36) (37) , compensatory boosting might occur among persons who are not periodically exposed to varicella (8) . Alternatively, external boosting might require a degree of varicella exposure that is uncommon among elderly persons, particularly because this population has less-frequent exposure to children than do younger adults (38) .
Age-and sex-standardized HZ incidence among elderly persons increased 39% from 10.0 per 1000 person-years to 13.9 per 1000 person-years during the 19-year study. On the basis of our observed values, we calculate that 14% of men and 20% of women who reach age 65 years will have HZ during their remaining lifetime (39) . The observed increase is robust, occurring among all age, sex, and race or ethnicity subgroups and all geographic regions. It does not seem to be an artifact of changing prevalence of immunocompromising conditions, because increases in age-and sex-standardized HZ incidence are seen even after restricting the analysis to a selected cohort of immunocompetent persons. Furthermore, increases in HZ incidence persisted when it was compared with 9 of 10 other acute outpatient conditions, suggesting that these increases were not due to underlying changes in health-seeking behavior or in the Medicare program over time.
Increases in HZ incidence in the elderly population have been reported in several studies in countries with and without varicella vaccination programs (3, 16, 17, 19, 20, 40, 41) ; however, other studies have not shown an increase (32, 33) . We have no explanation for the trend and expect that it awaits a better understanding of why a substantial minority of persons have HZ during their lifetime, whereas most do not. In particular, chronic diseases prevalent among elderly persons do not explain most cases of HZ (42) .
Data from the large, generalizable Medicare population provide an opportunity to more precisely characterize the well-recognized effect of age on HZ incidence. Although the association between HZ incidence and age seems to plateau after age 80 years, the risk for postherpetic neuralgia, hospitalization, and other complications continues to increase with age. We also provide precise data to confirm that older women are at greater risk for HZ than older men; most studies report increased HZ incidence among women in most age cohorts, including children, although the reason remains unknown (3, 17, 18, 20, 41, (43) (44) (45) (46) (47) . Finally, we provide data that black and Hispanic persons are at lower risk for HZ than white persons. A few reports are available on the reduced risk for HZ among black persons (43, 45, 48) , although data about HZ incidence in Hispanic persons are lacking (13) . The RR for American Indians or Alaska Natives should be interpreted with caution because health services provided by the Indian Health Service were not fully captured in the Medicare data (49).
We followed elderly Medicare beneficiaries who are at high risk for HZ for a long period spanning the licensure of varicella vaccination. In 2006, the U.S. Advisory Committee on Immunization Practices recommended the HZ vaccine for adults aged 60 years or older for prevention of HZ and its sequelae (21) . Uptake of the HZ vaccine has been slow, with only 1.9% coverage in adults aged 60 years or older in 2007 (50), increasing to 14.4% in 2010 (22).
Although we do not expect that such low coverage would substantially affect HZ incidence on a population level, these data provide a baseline for monitoring effects of the HZ vaccine program as coverage increases. A previous study of HZ incidence in all ages from 1993 to 2006 using MarketScan (Truven Health Analytics, Ann Arbor, Michigan), a database of health care claims from commercial insurers, had limitations in evaluating trends in adults aged 65 years or older because the size of the study population in this age group changed substantially over the observation period, allowing opportunities for unmeasured confounding (19) . MarketScan did not incorporate Medicare data until 1996 and even then contained health care claims for only the selected subset of Medicare beneficiaries with managed care. The Centers for Medicare & Medicaid Services Chronic Conditions Data Warehouse used in this study contains claims for a stable and more representative population of beneficiaries in traditional fee-for-service Medicare during the study period.
The use of administrative data has limitations. The accuracy of findings from studies based on health care claims depends on high and consistent levels of health-seeking behavior and access and on accurate disease coding. These criteria are probably met for most cases of HZ because it is painful and the study population had Medicare Parts A and B coverage for health care costs; however, mild cases may not come to medical attention, resulting in an underestimate of true incidence of HZ. In a population-based survey of 141 adults aged 60 years or older who had had HZ, 95% sought medical attention (50) .
Differences in health-seeking behavior or access may explain a portion of the variation in risk by sex or race or ethnicity. We could not directly assess the accuracy of HZ claims in our data through record reviews. However, previous studies of HZ have shown good concordance between coding and actual health care visits, with positive predictive values ranging from 85% to 100% (12, 18, 51) . Furthermore, estimates from self-reports and health care settings of HZ incidence have been similar to ours, providing reassurance about the sensitivity of HZ coding (17).
Our study was also limited by the data available for analysis. Although more than one half of cases of HZ in the United States occur in persons younger than 65 years and therefore were missed by our Medicare analysis, HZ tends to be much more severe in older adults; thus, the Medicare population is of particular importance (3). We showed that HZ incidence was not affected by state-level variation in varicella vaccination coverage controlled for sex and age but were not able to consider other factors that vary across states and might affect HZ incidence, such as age at parenthood, family size, or living with young children.
Age-specific HZ incidence has been increasing in the U.S. population older than 65 years even before implementation of the childhood varicella vaccination program. Introduction and widespread use of this vaccine did not seem to affect this increase. This information is reassuring for countries considering universal varicella vaccination.
Our findings have several implications. First, in the absence of explanations for increasing HZ incidence, properly monitoring the effect of the HZ vaccination program or projecting future HZ incidence will be difficult. Furthermore, HZ poses a substantial burden of disease in the elderly population; continued increases in HZ incidence would be worrisome and need to be understood. Fortunately, an effective vaccine is now available that can help prevent this disabling disease.
Context
The incidence of herpes zoster (HZ) in older adults is increasing. This could be due to routine childhood varicella vaccination, which prevents adults from experiencing a natural boost in varicella-specific immunity through exposure to children with chickenpox.
Contribution
Information from a Medicare database showed that the age-specific increase in HZ incidence began before the introduction of routine childhood varicella vaccination and does not vary by state vaccination coverage in models adjusted for sex, age, and calendar year.
Implication
The age-specific increase in HZ incidence in older adults is currently unexplained and argues for wider use of HZ vaccination in this population.
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